Efficacy of botulinum toxin for spasticity management in neurorehabilitation

Kulkarni, Jai
May 2004
International Journal of Therapy & Rehabilitation;May2004, Vol. 11 Issue 5, p211
Academic Journal
Presents the study assessing the effect of botulinum toxin type A when used in conjunction with physiotherapy on spasticity management. Identification of the most potent toxins available proved to be a remarkable therapeutic agent when used appropriately; Effect of spasticity on joint movement and positioning; Treatment for spinal cord injury.


Related Articles

  • COMMENTARIES. Deshpande, Pradeep; Bullock, Caroline // International Journal of Therapy & Rehabilitation;May2004, Vol. 11 Issue 5, p218 

    Comments on the article "Efficacy of Botulinum Toxin for Spasticity Management in Neurorehabilitation," published in the May 2004 issue of "International Journal of Therapy and Rehabilitation." Reduction of spasticity from patients with neurological conditions; Optimum emphasis of the...

  • Botulinum Toxin Type B: Where Do We Stand? Dressler, Dirk // European Neurology;2001, Vol. 46 Issue 3, p113 

    Discusses issues concerning the therapeutic use of botulinum toxin (BT) type B. Comparison with the use of BT type A; Immunological considerations; Conversion factors.

  • Botulinum toxin type B de novo therapy of cervical dystonia. Dressler, Dirk; Bigalke, Hans // Journal of Neurology;Aug2005, Vol. 252 Issue 8, p904 

    Botulinum toxin induced therapy failure type B antibody (BT–B, BT–B–AB) has so far only been reported after previous formation of antibodies against botulinum toxin type A (BT–A, BTA– AB).We wanted to explore the risk of BT-B-AB-induced therapy failure in...

  • A Review of Thoracic Outlet Syndrome and the Possible Role of Botulinum Toxin in the Treatment of This Syndrome. Foley, Jacqueline Mary; Finlayson, Heather; Travlos, Andrew // Toxins;Nov2012, Vol. 4 Issue 11, p1123 

    The objective of this paper is to discuss the classification, diagnosis, pathophysiology and management of Thoracic outlet syndrome (TOS). Thoracic outlet syndrome (TOS) is a complex entity that is characterized by different neurovascular signs and symptoms involving the upper limb. TOS is...

  • Botulinum Toxin in Medical Therapy. Skorin Jr., Leonid // Review of Optometry;7/15/2004, Vol. 141 Issue 7, p53 

    Focuses on the use of botulinum toxin in medical therapy in the U.S. Treatment of blepharospasm, strabismus, and other ocular muscle disorders; Inhibition of the release of acetylcholine from the nerve terminal; Availability of two immunologically distinct neurotoxins for clinical use in the...

  • Crow's Feet Treatment with Botulinum Toxin Type A. Petropoulos, I.; Noussios, G.; Chouridis, P.; Kontzoglou, G.; Karagiannidis, K. // Internet Journal of Aesthetic & Antiaging Medicine;Oct2008, Vol. 1 Issue 2, p1 

    Botulinum toxin type A is widely used for treatment of facial rhytids, often in an "off-label" fashion. The most important mechanisms of action and safety concerns for such treatments are presented, with recommendations for treatment of periorbital rhytids.

  • Single-session Botox safe, effective. Guttman, Cheryl // Dermatology Times;Apr2005 Supplement 2, Vol. 26, pS14 

    The article presents information related to Botulinum toxin type A (Botox, Botox Cosmetic; Allergan). Botox can be used safely and effectively in a range of doses to simultaneously treat a spectrum of upper facial rhytids in adult women, although use of a higher dose affords benefits for...

  • Household Biowaste Containers (Bio-Bins) – Potential Incubators For Clostridium Botulinum and Botulinum Neurotoxins. Böhnel, Helge // Water, Air & Soil Pollution;Oct2002, Vol. 140 Issue 1-4, p335 

    In previously conducted research, Clostridium botulinum spores were found in bio-waste compost. Household bio-waste, collected in `bio-bins', was suspected to be one of the reasons for contamination. Maggots of Calliphoridae were collected inside and outside of bio-bins from 8 different...

  • Botulinum Toxin for Suspected Pseudoachalasia. Vallera, Raymond A.; Brazer, Scott R. // American Journal of Gastroenterology;Aug1995, Vol. 90 Issue 8, p1319 

    We describe a 74-yr-old man with stage III adenocarcinoma of the lung who presented with suspected malignancy-induced secondary achalasia and responded clinically to intrasphincteric injections of botulinum toxin type A (Botox, Allergen Inc., Irvine, CA). We discuss the use of botulinum toxin in...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics